Thyroid Hormone in the Clinic and Breast Cancer

Aleck Hercbergs, Shaker A. Mousa, Matthew Leinung, Hung Yun Lin, Paul J. Davis

研究成果: 雜誌貢獻文章同行評審

21 引文 斯高帕斯(Scopus)

摘要

There is preclinical and recent epidemiological evidence that thyroid hormone supports breast cancer. These observations raise the issue of whether management of breast cancer in certain settings should include consideration of reducing the possible contribution of thyroid hormone to the advancement of the disease. In a preliminary experience, elimination of the clinical action of endogenous L-thyroxine (T4) in patients with advanced solid tumors, including breast cancer, has favorably affected the course of the cancer, particularly when coupled with administration of exogenous 3,5,3′-triiodo-L-thyronine (T3) (euthyroid hypothyroxinemia). We discuss in the current brief review the possible clinical settings in which to consider whether endogenous thyroid hormone—or exogenous thyroid hormone in the patient with hypothyroidism and coincident breast cancer—is significantly contributing to breast cancer outcome.
原文英語
頁(從 - 到)139-143
頁數5
期刊Hormones and Cancer
9
發行號3
DOIs
出版狀態已發佈 - 二月 13 2018

ASJC Scopus subject areas

  • 內分泌學、糖尿病和代謝
  • 腫瘤科
  • 內分泌
  • 內分泌和自主系統
  • 癌症研究

指紋

深入研究「Thyroid Hormone in the Clinic and Breast Cancer」主題。共同形成了獨特的指紋。

引用此